Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Group Theory and Model Theory (GTMT)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Mathematical foundations
Countries involved: France
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2011-10-01
End date: 2013-12-31
Duration (months): 27.0
Total project cost (EUR): 366597.6
EU funding (EUR): 366597.6
Participants: 1
Project status: CLOSED

The project is located between logic and mathematics, more precisely between model theory and group theory. There are extremely difficult questions arising about the model theory of groups, notably the question of the construction of new groups with prescribed algebraic properties and at the same time good model-theoretic properties. In particular, it is an important question, both in model theory and in group theory, to build new stable groups and eventually new nonalgebraic groups with a good dimension notion. The present project aims at filling these gaps. It is divided into three main directions. Firstly, it consists in the continuation of the classification of groups with a good dimension notion, notably groups of finite Morley rank or related notions. Secondly, it consists in a systematic inspection of the combinatorial and geometric group theory which can be applied to build new groups, keeping a control on their first order theory. Thirdly, and in connection to the previous difficult problem, it consists in a very systematic and general study of infinite permutation groups.

Keywords: algebraic groups,free groups,hrushovski's constructions,msc2010: 03cxx model theory,msc2010: 20f11 groups of finite morley rank,msc2010: 20bxx permutation groups,msc2010: 20a15 applications...
Demonstration Project for Power Supply to Telecom Stations through FC technology (FCPOWEREDRBS)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Collaborative project
Partnership: FCH (Art-185)
Countries involved: Italy,Denmark,European organisations area,Denmark,Switzerland
Call:  (FCH-JU-2010-1, 2010)
Start date: 2012-01-01
End date: 2015-12-31
Duration (months): 48.0
Total project cost (EUR): 10591649.0
EU funding (EUR): 4221270.0
Participants: 6
Project status: CLOSED

FC and H2 may represent an enabling technology for a wider diffusion of Radio Base Station “energized” by renewable energy sources. While the expected higher energy efficiency already has an attractive potential for these applications, the energy storage potential of H2 (either locally produced or stored in bottles) is even more interesting as it could extend significantly the number of hours of unattended operation which very much determines the overall energy cost for these installation. This is an instrumental feature of H2 and FC which could favour the further diffusion of mobile applications in remote sites. To clearly demonstrate this potential a minimum of 17 sites of really operating off-grid Radio Base Stations will be equipped with an integrated power generation system using Fuel Cell technology and H2 and tested for a significant period. This very large demonstration program will be used to assess the readiness of available technological solution to make the potential viable and demonstrate the industrial readiness of the fuel cell technology in this early market. These units will demonstrate a level of technical performance (start-up time, reliability, durability, number of cycles) that qualifies them for market entry, thereby accelerating the commercialization of this technology in Europe and elsewhere. The RBSPoweredFCH2 Project consortium integrates different EU FC and H2 related technology maker with a market leader for Telecom Systems and with R&D institution. This peculiar opportunity is also fundamental to pursue a bottom-up approach which allows to modify the energy requirements and load profile of the energy utilization to fit in an optimum way the performances expected for the Fuel Cell system. The demonstration project will involve the benchmarking of different technical configurations for fuel cells integrated with other local Renewable Energy sources (mainly PV but also wind). One of the key factor for this off-grid application market

Keywords: off-grid radio base stations fc h2 diesel renewable energy sources power innovative technology partners
Positive Scalar Curvature and Lagrangian Mean Curvature Flow (PSC AND LMCF)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Mathematical foundations
Countries involved: United Kingdom
Call:  (ERC-2011-StG_20101014, 2011)
Start date: 2012-01-01
End date: 2016-12-31
Duration (months): 60.0
Total project cost (EUR): 1100000.0
EU funding (EUR): 1100000.0
Participants: 1
Project status: CLOSED

The interplay between Geometry and Analysis has been among the most fruitful mathematical ideas in recent years, the most obvious example being Perelman's proof of Poincare' conjecture. The goal of this proposal is to establish a research group that will make significant progress in the following two distinct problems. Scalar Curvature: A classical theorem in Riemannian Geometry states that nonnegative scalar curvature metrics which are flat outside a compact set must be Euclidean. The equivalent problem for positive scalar curvature is known as the Min-Oo conjecture and, after being checked in many particular cases, was recently disproven by myself and coauthors. I plan to prove optimal results relating positive scalar curvature and area of minimal surfaces. I also plan to show that these manifolds admit an infinite number of minimal surfaces (Yau's conjecture). My approach consists of studying min-max methods in order to obtain existence of higher-index minimal surfaces. Mean curvature flow: An hard open problem consists in determining which Lagrangians in a Calabi-Yau admit a minimal Lagrangian (SLag) in their isotopy class and a complete answer would have a strong impact in Algebraic Geometry and Mirror Symmetry. A well known approach consists in deforming a given Lagrangian in the direction of its mean curvature and hope to show convergence to a SLag. The difficulty with this method is that finite-time singularities can occur. I plan to study the regularity theory for this flow and show singularities have codimension two. This would be the ground stage to continue the flow past the singular time. My approach consists in classifying the possible parabolic blow-ups and find monotone quantities which will rule out non SLag blow-ups.

Keywords: geometric analysis,differential geometry
A stealth attack tool for preventing clinical drug resistance through a unique self-regenerating surface (BACATTACK)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Israel,France,Sweden,Denmark,United Kingdom
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2015-12-31
Duration (months): 48.0
Total project cost (EUR): 3890118.0
EU funding (EUR): 2990698.0
Participants: 7
Project status: CLOSED

Outbreaks of clinical infections affect many thousands of patients in Europe yearly. The present effective treatment for infections is large doses of systemically applied drugs. There is a high risk of recurring infections and biofilm formation for patients dependent on long term in-dwelling catheters and the extended dependency on antibiotics result in clinical drug resistance. We present a new tool for minimizing drug resistance by upgrading existing and future medical devices through a unique self-regenerating surface that prevents biofilm formation by a two-fold stealth attack mechanism. This will be achieved by an interpenetrating polymer network (IPN) that allows for long term release of a range of antimicrobial strategies, such as antimicrobial peptides (AMPs) . The IPNs contain hydrogels where the AMP is stored until the release starts at the insertion of the device with an expected long-term effect. The first line of defence will be a fixed galvanic noble metal alloy coating that will prevent bacteria from colonizing the surface. Local and site-specific treatment with long term effect instead of systemic treatment implies improved patient management and citizen well-fare.

Keywords: biofilm prevention,catheters,interpenetrating polymer networks,antimicrobial peptides,release,clinical drug resistance,silicone,hydrogels
Targeting Brain Inflammation For Improved Functional Recovery in Acute Neurodegenerative Disorders (TARGETBRAIN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Israel,Italy,Germany,Switzerland,United Kingdom,Sweden,France
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-12-01
End date: 2016-11-30
Duration (months): 60.0
Total project cost (EUR): 15716317.8
EU funding (EUR): 11989162.0
Participants: 10
Project status: CLOSED

In acute neurodegenerative disorders, following a sudden insult, neurons are rapidly damaged and usually die but cellular loss can occur hours and days thereafter. These diseases cause massive morbidity and mortality and tremendous economic and societal burden, especially ischemic stroke, which is a leading cause of death and disability with no effective treatment to promote recovery. The brain responds to a stroke, i.e., occlusion of a cerebral artery, with an inflammatory process characterized by rapid activation of resident cells including microglia and astrocytes, production of proinflammatory mediators, and infiltration of various types of immune cells. Recent studies have suggested that the local inflammation is not only detrimental but can also be beneficial for the repair process. Our proposal unites 7 leading academic teams and 2 experienced SMEs and aims to develop a pre-clinical protocol for immunomodulation leading to enhancement of cellular plasticity and improved functional recovery in stroke patients. To achieve this goal we will study the temporal and spatial role of inflammatory cells in stroke-induced brain damage and determine the action of inflammatory cells in the activation and support of regenerative processes, including the formation of new neurons from endogenous and transplanted neural stem cells (NSCs). We will investigate the ability of transplanted NSCs to modulate the inflammatory response and to affect the characteristics of the stroke-induced lesion and subsequent recovery. The overriding social objective of our project is to develop a novel therapeutic strategy which will shorten the recovery phase, minimize the motor impairments, and improve the patients’quality of life after stroke.

Keywords: acute neurodegeneration,stroke,neuroinflammation,monocyte,microglia,astrocyte,macrophage,stem cell,neurogenesis,gliogenesis
New Technologies and Production Tools for Complex Protein Biologics (COMPLEXINC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Portugal,Spain,Germany,Germany,Spain,Switzerland
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-11-01
End date: 2015-10-31
Duration (months): 48.0
Total project cost (EUR): 7777285.0
EU funding (EUR): 5999682.8
Participants: 8
Project status: CLOSED

ComplexINC conceptualizes and systematically generates advanced tool-kits to enable high-throughput assembly of complex biologics and metabolic pathways in eukaryotic expression systems, for micro- to large scale production of high-quality protein specimens for drug discovery and as bio-therapeutics. Essential parts of these tool-kits will be innovative next-generation HT DNA assembly pipelines for automated multigene expression construct generation, a superior synthetic viral genome, genetically engineered animal and yeast cell lines with unique capabilities with respect to protein maturation and modification, as well as advanced methods for bioprocessing and integrated quality control. Putting these tools and production technologies in place will have a dramatic impact on the availability of challenging proteins and protein complexes including such of human origin, with tailor-made properties specifically geared towards their application in drug discovery and in the treatment of human diseases. The superior next generation technology platforms created within ComplexINC, the generated IP, protein targets and therapeutics will be commercially exploited, and serve as a nucleus to initiate a new start-up enterprise to commercialize high-end biologics discovery and production.

Keywords: eukaryotic expression systems,cell line engineering,high-throughput,virus-like particles,vaccine,multiprotein complexomics,bioprocess,synthetic biology,bio-pharmaceuticals,drug discovery
A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease (NILVAD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Ireland,Luxembourg,Germany,United Kingdom,Italy,France,Germany,Hungary,Sweden,Ireland,Greece,Netherlands,United States
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2017-06-30
Duration (months): 66.0
Total project cost (EUR): 7916016.43
EU funding (EUR): 5999978.0
Participants: 17
Project status: CLOSED

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010). Even modest therapeutic advances that delay disease onset and progression could significantly reduce the global burden of the disease and the level of care required by patients. While there are symptomatic-based drug therapies available for AD, these medications do not prevent the disease process itself. There is therefore an imperative to develop new treatments for AD that have disease modifying effects. This double-blind placebo controlled study will test the efficacy and safety of nilvadipine in 500 subjects with mild to moderate AD over a treatment period of 18 months. There is a strong scientific rationale for this study: Nilvadipine, a licensed calcium channel enhances Aß clearance from brain and restores cortical perfusion in mouse models of AD. Nilvadipine is safe and well tolerated in AD patients and clinical studies with this medication have shown stabilization of cognitive decline and reduced incidence of AD, pointing to both symptomatic and disease modifying benefits. Male and female patients with mild to moderate AD aged between 50 and 90 with a range of medical morbidities and frailty will be included in the study. If this trial is successful, nilvadipine would represent an advance in the treatment of AD patients and would have a major impact on the health and social care costs incurred in Europe by this neurodegenerative disorder. Furthermore, the creation of the NILVAD network will support future clinical trials and research innovation in AD across Europe.
The genetic basis of meningococcal and other life threatening bacterial infections of childhood (EUCLIDS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,Netherlands,Netherlands,Netherlands,Austria,Spain,United Kingdom,Italy,Switzerland,United Kingdom,Singapore,United Kingdom
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2011-12-01
End date: 2017-05-31
Duration (months): 66.0
Total project cost (EUR): 17323678.54
EU funding (EUR): 11988647.0
Participants: 16
Project status: CLOSED

Bacterial infection is the major cause of disability and death in children worldwide. We will use meningococcal disease (MD) as a model to understand genetic factors underlying susceptibility and severity of childhood bacterial infection which will then be applied to other childhood infections. We have established cohorts of patients with MD in Central and Southern Europe (CE,SE), UK and Africa as well as cohorts with other bacterial infections. We have established an inter-disciplinary team with expertise in Infectious Diseases, Immunogenetics, Bio-informatics, Microbiology, Public Health and Vaccinology including SME and industrial partners. We have already undertaken a genome wide study (GWAS) to identify genes causing susceptibility to meningococcal disease in a UK cohort. We identified complement factor H (fH) and fH-related (fHr) genes controlling MD susceptibility. This finding is fundamental to prevention as vaccines containing the MD fH receptor are undergoing trials. We will undertake GWAS on the CE, and SE MD cohorts, allowing meta analysis, and cross validation, and undertake GWAS on 2,500 Meningococcal Vaccine recipients. We will use next generation sequencing to identify the causal variants within the fH/fHr region and other regions implicated by pathway and severity analyses of the three MD GWAS and vaccine GWAS. We will match bacterial and host genetic variation and identify mechanisms of action of fH variants and other genes controlling susceptibility and severity using RNA expression, functional analyses and animal models. We will identify Mendelian defects and rare mutations as well as copy number variation and epi-genetic effects using next generation sequencing and RNA sequencing in “extreme phenotype” cohorts with MD , pneumococcal ,staphylococcal and salmonella disease. The study will identify mechanisms underlying susceptibility, provide new targets for treatment and prevention, and identify those at risk of disease or poor outcome.

Keywords: meningococcal disease,bacterial infection,genome wide association study (gwas),severity and susceptibility
Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at high-risk for progression. (DEXLIFE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Ireland,Spain,Finland,United Kingdom,United States
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2015-12-31
Duration (months): 48.0
Total project cost (EUR): 7912027.39
EU funding (EUR): 5486631.0
Participants: 10
Project status: CLOSED

Type 2 diabetes (T2DM) is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of T2DM are huge, approaching 10% of all health costs. Prevention of diabetes is a priority for national healthcare agencies and for the health insurance industry. Investment in prevention and lifestyle programmes requires a solid evidence-base for targeting and customising these interventions in a cost-effective manner. Translation of the findings from T2DM prevention studies to the benefit of general public health has not yet been possible. DEXLIFE will identify novel diagnostic and predictive biomarkers (i) to detect the progression toward diabetes in high risk individuals and (ii) that are responsive to lifestyle interventions known to be effective in diabetes prevention. New biomarkers alone will be insufficient to alter the course of diabetes progression. We bring a strong translational focus to this proposal, by setting the main intervention in the real-life context of a major health insurance system. The accumulated phenotyping repertoire from an extensive panel of –omic analyses will be refined and modelled into a new diagnostic panel for the allocation of high risk subjects to individualised preventive regimens. Our multi-disciplinary team has a strong track record in clinical diabetes and metabolism. Several unique clinical cohorts will provide the basis for a series of clinical, physiological and mechanistic investigations, which will identify, monitor and analyse the impact of biomarkers over time. An exercise and dietary intervention study will be included in two specific cohorts, enabling us to assess the impact of such interventions on plasma biomarkers and functional tissue-based markers. Project clinical and industry partners will support the translation of our findings into clinical practice.

Keywords: diabetes,prevention,clinical physiology,exercise,diet,metabolomics,epigenetics,mitochondria,transcriptomics,lipidomics,health insurance
EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations (EPIC-CVD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Sweden,United Kingdom,France,Italy,Germany,United Kingdom,Greece,Spain,Denmark,Sweden,United Kingdom,Italy,Germany,Italy,Norway,Spain,Spain,Spain,New Zealand,Spain,Italy,Finland
Call:  (FP7-HEALTH-2011-two-stage, 2011)
Start date: 2012-01-01
End date: 2015-12-31
Duration (months): 48.0
Total project cost (EUR): 7947602.67
EU funding (EUR): 5987266.0
Participants: 30
Project status: CLOSED

EPIC-CVD's overarching goal is to provide clinicians and policy-makers with a menu of evidence-based options for cost-effective individualised risk assessment that enables the EU's increasingly resource-constrained economies to achieve more personalised predictive medicine in harmony with Europe's diverse cultures and healthcare systems. We will achieve this through developing and validating innovative risk scores and efficient screening strategies by studying 75 high priority soluble biomarkers and 215,000 carefully selected genetic variants in the most powerful population-based prospective study ever conducted of incident coronary heart disease, stroke, and type 2 diabetes across 10 diverse European countries. EPIC-CVD will provide the first consideration across Europe of risk scores with information on the interplay of nature and nurture together with biomarkers of lifestyle, biological pathways, vascular injury, and ageing. Our multidisciplinary consortium involves world-leading expertise in population health science, laboratory science (including VITAS, an SME partner, renowned for nutritional biomarker assays), translational science, and implementation science. This rare combination of expertise will enable systematic consideration of the implications of risk scores and screening strategies for predictive accuracy, feasibility, safety, acceptability, and cost-effectiveness. The impact on clinical decision making and clinical outcomes will be demonstrated in a new randomised trial of risk scores in relation to "patient-centred" outcomes that assess attitudes, behaviours, and biological risk factors. Key stakeholders (eg, healthcare professionals, regulators, industry) will be closely engaged by the project. Policy recommendations mindful of the broader societal implications of targeted screening will be tailored to Europe's diverse needs and systematically disseminated to various audiences. This initiative will derive major synergy from related efforts.

Keywords: lifestyle,behaviour,nutrition,genetics,plasma biomarkers